碳青黴烯類抗生素市場－全球產業規模、佔有率、趨勢、機會及預測，依藥物類別、應用、配銷通路、地區及競爭格局分類，2020-2030年預測

2024年全球碳青黴烯類抗生素市場規模為39.2億美元，預計2030年將以4.85%的複合年成長率成長至52.1億美元。碳青黴烯類抗生素是一類重要的廣效BETA-內醯胺類抗生素，主要用於治療嚴重的細菌感染，特別是多重抗藥性病原體引起的感染。市場擴張的根本驅動力是日益嚴峻的全球抗菌素抗藥性挑戰，這使得人們迫切需要針對複雜感染的有效最後一道防線治療方案。

主要市場促進因素

抗菌素抗藥性日益嚴峻的挑戰，大大推動了全球碳青黴烯類藥物市場的發展。隨著病原體發展出逃避傳統療法的機制，碳青黴烯類藥物作為最後的治療手段，變得不可或缺。

主要市場挑戰

新型抗生素研發管線的萎縮嚴重阻礙了全球碳青黴烯類抗生素市場的成長。由於致病菌不斷進化並對現有療法產生抗藥性，缺乏新型創新碳青黴烯類藥物或針對耐碳青黴烯類細菌的有效替代藥物，因此直接限制了市場擴張。

主要市場趨勢

仿製碳青黴烯類抗生素的日益普及從根本上影響市場動態，提高了這些關鍵的最後一道防線抗生素的可及性和可負擔性。這一趨勢使更多患者群體能夠獲得必要的治療，尤其是在預算有限的地區。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球碳青黴烯類抗生素市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依藥物類別（美羅培南、亞胺培南、厄他培南）
  • 依應用領域（泌尿道感染、血液感染、肺炎、腹腔內感染、其他）
  • 按配銷通路（醫院藥房、零售藥房、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美碳青黴烯類藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲碳青黴烯類抗生素市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區碳青黴烯類抗生素市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲碳青黴烯類藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲碳青黴烯類抗生素市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球碳青黴烯類抗生素市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Kopran Limited
• Aurobindo Pharma Limited
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.
• Venus Remedies Ltd.

第16章：策略建議

第17章調查會社について,免責事項

The Global Carbapenem Market, valued at USD 3.92 Billion in 2024, is projected to experience a CAGR of 4.85% to reach USD 5.21 Billion by 2030. Carbapenems are a critical class of broad-spectrum beta-lactam antibiotics, primarily reserved for treating severe bacterial infections, particularly those caused by multidrug-resistant pathogens. The market's expansion is fundamentally driven by the escalating global challenge of antimicrobial resistance, necessitating effective last-resort treatments for complex infections.

Key Market Drivers

The escalating challenge of antimicrobial resistance represents a profound impetus for the global carbapenem market. As pathogens develop mechanisms to evade conventional treatments, carbapenems, often serving as last-line therapies, become indispensable. This urgent need is dramatically underscored by the concerning rise in highly resistant organisms; according to the Centers for Disease Control and Prevention, in September 2025, a report in Annals of Internal Medicine revealed NDM-producing carbapenem-resistant Enterobacterales infections surged by more than 460% in the United States between 2019 and 2023.

Key Market Challenges

The diminishing pipeline of novel antibiotics poses a significant impediment to the growth of the Global Carbapenem Market. As bacterial pathogens continuously evolve and develop resistance to existing treatments, the lack of new and innovative carbapenem-class drugs, or alternative agents effective against carbapenem-resistant organisms, directly curtails market expansion. This absence of a robust development pipeline means that the efficacy lifespan of current carbapenems is shortened by the escalating challenge of antimicrobial resistance, leading to a reduced demand as their clinical utility wanes.

Key Market Trends

The increasing penetration of generic carbapenems fundamentally influences market dynamics, improving accessibility and affordability of these critical last-line antibiotics. This trend enables broader patient populations to receive necessary treatments, especially in regions with budget constraints. According to Medicines for Europe, in October 2024, generic medicines constituted 70% of all dispensed medicines in Europe, and over 90% in the United States and India.

Key Market Players

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Kopran Limited
• Aurobindo Pharma Limited
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.
• Venus Remedies Ltd.

Report Scope:

In this report, the Global Carbapenem Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbapenem Market, By Drug Class:

• Meropenem
• Imipenem
• Ertapenem

Carbapenem Market, By Application:

• Urinary Tract Infections
• Blood Stream Infections
• Pneumonia
• Intra-abdominal Infections
• Others

Carbapenem Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Carbapenem Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Carbapenem Market.

Available Customizations:

Global Carbapenem Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carbapenem Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Meropenem, Imipenem, Ertapenem)
  • 5.2.2. By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Carbapenem Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Carbapenem Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Carbapenem Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Carbapenem Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Carbapenem Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Carbapenem Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Carbapenem Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Carbapenem Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Carbapenem Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Carbapenem Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Carbapenem Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Carbapenem Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Carbapenem Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Carbapenem Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Carbapenem Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Carbapenem Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Carbapenem Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Carbapenem Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Carbapenem Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Carbapenem Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Carbapenem Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Carbapenem Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Carbapenem Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Carbapenem Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Carbapenem Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Menarini Group
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Sun Pharmaceutical Industries Ltd
• 15.4. Lupin Limited
• 15.5. Kopran Limited
• 15.6. Aurobindo Pharma Limited
• 15.7. Daewoong Pharmaceuticals Co., Ltd.
• 15.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
• 15.9. Merck & Co., Inc.
• 15.10. Venus Remedies Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer